Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.
Tolmachev V, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, Sandström M, Gräslund T, Orlova A.
J Nucl Med. 2012 Jan;53(1):90-7. Epub 2011 Dec 15.
Related citations
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR.
J Nucl Med. 2011 Dec;52(12):1970-8. Epub 2011 Nov 11.
Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner.
Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI.
J Nucl Med. 2011 Dec;52(12):1914-22. Epub 2011 Nov 11. Erratum in: J Nucl Med. 2012 Mar;53(3):507.
In vivo near-infrared fluorescence imaging of integrin α2β1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe.
Huang CW, Li Z, Conti PS.
J Nucl Med. 2011 Dec;52(12):1979-86. Epub 2011 Nov 7.
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, Gönen M, Schöder H, Humm JL, Scher HI, Larson SM.
J Nucl Med. 2011 Nov;52(11):1727-32. Epub 2011 Oct 7.
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, Ezziddin S, Bucerius J, von Mallek D.
J Nucl Med. 2011 Nov;52(11):1721-6. Epub 2011 Oct 5.
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J.
J Nucl Med. 2011 Oct;52(10):1608-15. Epub 2011 Sep 9.
Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM, Sharkey RM, Goldenberg DM, Frielink C, Molkenboer JD, Franssen GM, van Weerden WM, Oyen WJ, Boerman OC.
J Nucl Med. 2011 Oct;52(10):1601-7. Epub 2011 Aug 24.
Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, Honndorf VS, Quintanilla-Martinez L, Schönberger T, Duchamp O, Machulla HJ, Pichler BJ.
J Nucl Med. 2011 Oct;52(10):1654-63. Epub 2011 Aug 22.
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, Babich JW.
J Nucl Med. 2011 Jul;52(7):1087-93. Epub 2011 Jun 16.
Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT.
Seo Y, Aparici CM, Chen CP, Hsu C, Kased N, Schreck C, Costouros N, Hawkins R, Shinohara K, Roach Iii M.
J Nucl Med. 2011 Jul;52(7):1068-72. Epub 2011 Jun 16.
Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.
Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, Ohe K, Nakanishi T, Tamai I, Namiki M, Kawai K.
J Nucl Med. 2011 May;52(5):822-9.
Intraoperative imaging for sentinel node identification in prostate carcinoma: its use in combination with other techniques.
Vermeeren L, Valdés Olmos RA, Meinhardt W, Horenblas S.
J Nucl Med. 2011 May;52(5):741-4. Epub 2011 Apr 15.
In vivo imaging of intraprostatic-specific gene transcription by PET.
Pouliot F, Karanikolas BD, Johnson M, Sato M, Priceman SJ, Stout D, Sohn J, Satyamurthy N, deKernion JB, Wu L.
J Nucl Med. 2011 May;52(5):784-91. Epub 2011 Apr 15.
Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.
Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS.
J Nucl Med. 2011 Apr;52(4):625-33. Epub 2011 Mar 18.
In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.
J Nucl Med. 2011 Mar;52(3):470-7. Epub 2011 Feb 14.
18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S.
J Nucl Med. 2011 Feb;52(2):270-8. Epub 2011 Jan 13.
In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C, Huang M, Zhang R, Song S, Lu W, Flores L 2nd, Gelovani J, Li C.
J Nucl Med. 2011 Feb;52(2):241-8. Epub 2011 Jan 13.
Error occurred: cannot get document summary
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
Jadvar H.
J Nucl Med. 2011 Jan;52(1):81-9. Epub 2010 Dec 13. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on